Summary of risk factors for AGVHD, transplantation-related mortality, and overall mortality for SD and URD cohorts
| Variable* . | AGVHD grades B-D .  | AGVHD grades C-D .  | Transplantation-related mortality .  | Overall mortality .  | ||||
|---|---|---|---|---|---|---|---|---|
| SD . | URD . | SD . | URD . | SD . | URD . | SD . | URD . | |
| MA + TBI + PBSC | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | 
| MA + TBI + BM | — | ↓ | — | ↓ | — | — | ↓ | — | 
| MA + nonTBI + PBSC | — | — | — | — | — | — | ↓ | — | 
| MA + nonTBI + BM | ↓ | ↓ | ↓ | ↓ | — | — | — | — | 
| RIC + PBSC | ↓ | ↓ | — | — | — | ↓ | — | — | 
| RIC + BM | — | ↓ | — | ↓ | — | — | — | — | 
| Tacrolimus-based GVHD prophylaxis | ↓ | ↓ | ↓ | — | ↓ | — | ↓ | — | 
| Older recipient age | — | — | — | — | ↑ | ↑ | ↑ | ↑ | 
| Older donor age | — | — | — | — | — | ↑ | — | ↑ | 
| Higher KPS | — | — | — | — | ↓ | ↓ | ↓ | ↓ | 
| Disease type other than ALL | — | ↑ | — | ↑ | ↓ | — | ↓ | ↓ | 
| Disease status other than early | — | — | ↑ | — | ↑ | ↑ | ↑ | ↑ | 
| Female donor for male recipient | — | ↑ | — | ↑ | ↑ | ↑ | — | |
| CMV other than NN | — | — | — | — | — | ↑ | — | ↑ | 
| ABO mismatch | — | — | — | — | — | ↑ | — | ↑ | 
| HLA mismatch | NA | ↑ | — | ↑ | NA | ↑ | NA | ↑ | 
| Variable* . | AGVHD grades B-D .  | AGVHD grades C-D .  | Transplantation-related mortality .  | Overall mortality .  | ||||
|---|---|---|---|---|---|---|---|---|
| SD . | URD . | SD . | URD . | SD . | URD . | SD . | URD . | |
| MA + TBI + PBSC | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | 
| MA + TBI + BM | — | ↓ | — | ↓ | — | — | ↓ | — | 
| MA + nonTBI + PBSC | — | — | — | — | — | — | ↓ | — | 
| MA + nonTBI + BM | ↓ | ↓ | ↓ | ↓ | — | — | — | — | 
| RIC + PBSC | ↓ | ↓ | — | — | — | ↓ | — | — | 
| RIC + BM | — | ↓ | — | ↓ | — | — | — | — | 
| Tacrolimus-based GVHD prophylaxis | ↓ | ↓ | ↓ | — | ↓ | — | ↓ | — | 
| Older recipient age | — | — | — | — | ↑ | ↑ | ↑ | ↑ | 
| Older donor age | — | — | — | — | — | ↑ | — | ↑ | 
| Higher KPS | — | — | — | — | ↓ | ↓ | ↓ | ↓ | 
| Disease type other than ALL | — | ↑ | — | ↑ | ↓ | — | ↓ | ↓ | 
| Disease status other than early | — | — | ↑ | — | ↑ | ↑ | ↑ | ↑ | 
| Female donor for male recipient | — | ↑ | — | ↑ | ↑ | ↑ | — | |
| CMV other than NN | — | — | — | — | — | ↑ | — | ↑ | 
| ABO mismatch | — | — | — | — | — | ↑ | — | ↑ | 
| HLA mismatch | NA | ↑ | — | ↑ | NA | ↑ | NA | ↑ | 
NN indicates negative/negative serostatus; MA, myeloablative; —, no association; Ref, reference; NA, not applicable; ↑, increased risk/odd of association with outcome; and ↓, decreased risk/odd of association with outcome.
See individual tables of multivariate analyses for reference groups.